Wanbury Limited - Asset Resilience Ratio
Wanbury Limited (WANBURY) has an Asset Resilience Ratio of 3.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Wanbury Limited to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Wanbury Limited's Asset Resilience Ratio has changed over time. See Wanbury Limited balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Wanbury Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Wanbury Limited (WANBURY) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs58.77 Million | 1.29% |
| Short-term Investments | Rs86.71 Million | 1.9% |
| Total Liquid Assets | Rs145.48 Million | 3.19% |
Asset Resilience Insights
- Limited Liquidity: Wanbury Limited maintains only 3.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Wanbury Limited Industry Peers by Asset Resilience Ratio
Compare Wanbury Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Wanbury Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Wanbury Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 4.78% | Rs197.70 Million ≈ $2.14 Million |
Rs4.14 Billion ≈ $44.76 Million |
+4.05pp |
| 2024-03-31 | 0.73% | Rs24.97 Million ≈ $270.03K |
Rs3.43 Billion ≈ $37.15 Million |
-1.15pp |
| 2023-03-31 | 1.88% | Rs57.06 Million ≈ $617.06K |
Rs3.04 Billion ≈ $32.82 Million |
-4.55pp |
| 2022-03-31 | 6.43% | Rs226.56 Million ≈ $2.45 Million |
Rs3.53 Billion ≈ $38.13 Million |
+2.92pp |
| 2021-03-31 | 3.50% | Rs101.31 Million ≈ $1.10 Million |
Rs2.89 Billion ≈ $31.27 Million |
-5.85pp |
| 2020-03-31 | 9.36% | Rs260.73 Million ≈ $2.82 Million |
Rs2.79 Billion ≈ $30.14 Million |
+9.51pp |
| 2019-03-31 | -0.15% | Rs-4.41 Million ≈ $-47.70K |
Rs2.86 Billion ≈ $30.93 Million |
-0.01pp |
| 2018-03-31 | -0.14% | Rs-3.88 Million ≈ $-42.00K |
Rs2.73 Billion ≈ $29.49 Million |
+3.49pp |
| 2017-03-31 | -3.64% | Rs-149.81 Million ≈ $-1.62 Million |
Rs4.12 Billion ≈ $44.55 Million |
-3.64pp |
| 2016-03-31 | 0.00% | Rs94.00K ≈ $1.02K |
Rs3.82 Billion ≈ $41.35 Million |
-0.28pp |
| 2012-03-31 | 0.28% | Rs22.99 Million ≈ $248.61K |
Rs8.11 Billion ≈ $87.71 Million |
-0.07pp |
| 2007-03-31 | 0.35% | Rs11.30 Million ≈ $122.17K |
Rs3.20 Billion ≈ $34.65 Million |
-5.97pp |
| 2006-03-31 | 6.32% | Rs123.28 Million ≈ $1.33 Million |
Rs1.95 Billion ≈ $21.08 Million |
-- |
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more